Autolus Therapeutics plc (AUTL) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Autolus Therapeutics reported revenue of $75.4M, up 644.9% from $10.1M the year before. Net income was -$287.5M (a -381.4% net margin), or -$1.08 per diluted share. Gross margin was -27.8% and operating margin was -358.9%. Operating activities generated -$283.6M of cash, leaving -$302.6M of free cash flow. At fiscal year end, Autolus Therapeutics held $589.1M in total assets against $410.9M in total liabilities, including $104.1M of cash and equivalents.
Open the full interactive Autolus Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Autolus Therapeutics Key Stats
| Share Price | $1.62 |
|---|---|
| Market Cap | $431.2M |
| Revenue YoY Growth | +644.9% |
| 52-Week Range | $1.21 – $2.54 |
| Shares Outstanding | 266.2 million (basic, 2026 Q2) |
Autolus Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $10.1M | $75.4M |
| Cost of Goods Sold | — | $11.4M | $96.4M |
| Gross Profit | — | -$1.3M | -$21.0M |
| Operating Income | -$179.7M | -$241.4M | -$270.5M |
| Pre-Tax Income | -$208.4M | -$219.1M | -$285.6M |
| Income Tax | -$19,500 | $1.5M | $2.0M |
| Net Income | -$208.4M | -$220.7M | -$287.5M |
| Diluted EPS | -$1.20 | -$0.86 | -$1.08 |
Autolus Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $21.2M | $24.3M | $26.2M | $45.7M |
| Net Income | -$79.1M | -$90.3M | -$71.6M | -$39.1M |
| Diluted EPS | -$0.30 | -$0.34 | -$0.27 | -$0.15 |
Autolus Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $239.6M | $227.4M | $104.1M |
| Current Assets | $275.3M | $660.9M | $435.9M |
| Total Assets | $375.4M | $782.7M | $589.1M |
| Current Liabilities | $44.7M | $60.7M | $73.4M |
| Total Liabilities | $263.9M | $355.4M | $410.9M |
| Shareholders' Equity | $111.5M | $427.3M | $178.1M |
Autolus Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$145.6M | -$206.3M | -$283.6M |
| Cash From Investing | -$11.0M | -$394.6M | $158.5M |
| Cash From Financing | -$883,000 | $589.6M | -$4.3M |
| Free Cash Flow | -$156.6M | -$228.3M | -$302.6M |
Figures from Autolus Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Autolus Therapeutics financials page for every line item.
Autolus Therapeutics Company Profile
| Ticker | AUTL |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | London, United Kingdom |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001730463 |
Frequently Asked Questions
What was Autolus Therapeutics' revenue in fiscal 2025?
Autolus Therapeutics (AUTL) reported revenue of $75.4M for fiscal 2025.
What is Autolus Therapeutics' annual revenue history?
Autolus Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $10.1M; 2025: $75.4M.
What was Autolus Therapeutics' net income in fiscal 2025?
Autolus Therapeutics reported net income of -$287.5M for fiscal 2025.
What was Autolus Therapeutics' earnings per share (EPS) in fiscal 2025?
Autolus Therapeutics' diluted EPS was -$1.08 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Autolus Therapeutics generate in fiscal 2025?
Autolus Therapeutics generated -$302.6M of free cash flow in fiscal 2025.
What was Autolus Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Autolus Therapeutics reported revenue of $45.7M.
How many shares of Autolus Therapeutics are outstanding?
Autolus Therapeutics reported a weighted average of 266.2 million basic shares outstanding in 2026 Q2.
What is Autolus Therapeutics' market cap?
Based on its latest closing price, Autolus Therapeutics (AUTL) has a market capitalization of about $431.2M.
When does Autolus Therapeutics' fiscal year end?
Autolus Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Autolus Therapeutics headquartered?
Autolus Therapeutics lists its business address in London, United Kingdom in its SEC filings.
Autolus Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →